ArticleHistology and histopathology2026
Mechanism of lncRNA PLACT1 in regulating the proliferation of pancreatic adenocarcinoma cells through the KLF2/KIAA1522 axis.
Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPancreatic adenocarcinoma (PAAD) is among the most common cancers worldwide. This study aims to investigate the role of long noncoding RNA pancreatic cancer-associated transcript 1 (LncRNA PLACT1) in PAAD cell proliferation.
methodsPAAD and normal cells were cultured. The levels of PLACT1, Krüppel-like factor 2 (KLF2), and KIAA1522 were detected. After PLACT1 expression was interfered with, cell proliferation was detected using the cell counting kit-8, clone formation assay, and 5-ethynyl-2-deoxyuridine (EdU) staining. The binding of PLACT1 to euchromatic histone lysine methyltransferase 2 (EHMT2) was analyzed. The enrichment of EHMT2 and histone H3 lysine 9 dimethylation (H3K9me2) on the KLF2 promoter was analyzed by chromatin immunoprecipitation. KLF2 expression was detected after EHMT2 intervention. The binding of KLF2 to the KIAA1522 promoter was analyzed. The nude mouse xenograft model was constructed to detect the role of PLACT1
resultsPLACT1 and KIAA1522 were highly expressed, and KLF2 was poorly expressed in PAAD cells. Silencing PLACT1 decreased cell proliferation, the number of cell clones, and EdU-positive cells. Mechanistically, PLACT1 inhibited KLF2 expression by recruiting EHMT2 to induce H3K9me2 in the KLF2 promoter region, resulting in reduced KLF2 enrichment at the KIAA1522 promoter and increased KIAA1522 expression. KLF2 downregulation or KIAA1522 overexpression alleviated the inhibitory effect of PLACT1 silencing on PAAD cell proliferation. PLACT1 silencing prevented PAAD tumorigenesis by regulating the KLF2/KIAA1522 pathway.
conclusionPLACT1 silencing inhibited PAAD by inhibiting KLF2 and promoting KIAA1522 expression, suggesting the therapeutic effect of PLACT1 silencing on PAAD.
Indexed as
Identifiers
41164921What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.